Evidence map›Paper›PMID 39311321›Full record

ArticleVision (Basel, Switzerland)2024

Colour Vision Changes across Lifespan: Insights from FM100 and CAD Tests.

Renārs Trukša, Sergejs Fomins, Zane Jansone-Langina, Laura Tenisa

Abstract read
In one paragraph

Article in Vision (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Renārs TrukšaDepartment of Optometry and Vision Science, Faculty of Science and Technology, University of Latvia, LV-1004 Riga, Latvia.ORCID 0000-0001-5694-0614
Sergejs FominsInstitute of Solid-State Physics, University of Latvia, LV-1063 Riga, Latvia.
Zane Jansone-LanginaDepartment of Optometry and Vision Science, Faculty of Science and Technology, University of Latvia, LV-1004 Riga, Latvia.ORCID 0000-0002-6596-3364
Laura TenisaDepartment of Optometry and Vision Science, Faculty of Science and Technology, University of Latvia, LV-1004 Riga, Latvia.

Funding

Optometry and vision science department Project No. ORZN-2023/2
6 · The paper itself

Abstract

(1) Background: in this research study, colour vision was evaluated in individuals aged 19 to 70 years with and without red-green colour vision disorders. (2) Methods: study participant colour vision was assessed with anomaloscope, HRR, FM100 hue, and CAD tests. (3) Results: No significant correlation was found between participant age and chromatic sensitivity of the red-green colour opponent channel. However, a decrease in blue-yellow colour opponent channel chromatic sensitivity was confirmed with the FM100 hue test and CAD test. Analysis of FM100 hue test error scores across age groups revealed a decline in chromatic sensitivity in the short-wave region of visible light with increasing age. Comparison of the colour-deficient individual results of the CAD and anomaloscope tests confirmed that CAD test sensitivity and specificity reaches 100%. However, some individuals with deutan-type deficits were misclassified as having protan-type deficits. This study confirmed the effectiveness of the FM100 test in identifying individuals with moderate to severe colour vision deficits, with sensitivity and specificity rates of 81.25% and 95.38%. (4) Conclusions: It was found that the FM100 hue test effectively identifies individuals with moderate and severe red-green colour vision deficiencies. On the other hand, individuals with mild colour vision deficiencies may go undetected with the FM100 hue test.

Indexed as

chromatic sensitivitycolour opponent channelcolour vision deficiencycolour vision tests

Identifiers

PMID39311321
PMCPMC11417771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.